Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SH-1028 in advanced EGFR-mutant non-small cell lung cancer
CTR20190139Phase 2Active
- Sponsor
- Shenghe Pharmaceutical
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rilertinib in non-small cell lung cancer (NSCLC), sponsored by Shenghe Pharmaceutical. Started Apr 2019; status: active.
02
Drugs
rilertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190139.